Prevail Therapeutics is a biotechnology company that develops and commercializes novel therapies for the treatment of neurodegenerative disorders.
Business Model:
Revenue: $74.3M
Employees: 51-200
Prevail Therapeutics was acquired by
Eli Lilly.
The acquisition happend on 2020-12-15.
Details of the transaction were not public
Address: 430 East 29th Street
City: New York
State: NY
Zip: 10016
Country: US
Prevail Therapeutics is a biotechnology company that develops and commercializes novel therapies for the treatment of neurodegenerative disorders.
Contact Phone:
+19173369310
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
6/20/2019
IPO Valuation:
$578M
Ticker Symbol:
PRVL
IPO Price:
$17/share
Amount Raised:
$125M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2018 | Series A | 9 | $75M |
OrbiMed RA Capital Management Pontifax Omega Funds EcoR1 Capital Boxer Capital Biotechnology Value Fund Alexandria Venture Investments Adage Capital Management OrbiMed |
3/2019 | Series B | 11 | $50M |
EcoR1 Capital Alexandria Venture Investments Adage Capital Management OrbiMed RA Capital Management Biotechnology Value Fund Pontifax Omega Funds Surveyor Capital AbbVie Biotech Ventures Boxer Capital EcoR1 Capital Alexandria Venture Investments Adage Capital Management OrbiMed RA Capital Management Biotechnology Value Fund Pontifax Omega Funds Surveyor Capital AbbVie Biotech Ventures |
8/2017 | Seed Round | $4M | 6/2019 | IPO | $125M |
|
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|